Special Investigation For Patients With Renal And/Or Hepatic Disorders On Aromasin

Pfizer

Status: Completed

Conditions: Breast Neoplasms

Treatments: Drug: Exemestane

Study type: Observational

Funder types: Industry

Identifiers

NCT00932165

A5991078

Details and patient eligibility

About

The objective of this surveillance is to collect information about 1) adverse drug reaction not expected from the LPD (unknown adverse drug reaction), 2) the incidence of adverse drug reactions in this surveillance, and 3)factors considered to affect the safety and/or efficacy of this drug.

Full description

All the patients whom an investigator prescribes the first Exemestane (Aromasin) should be registered.

Enrollment: 451 patients

Sex: All

Volunteers: No Healthy Volunteers

Inclusion criteria

• Subjects with postmenopausal breast cancer (including ovariectomy etc.).

Exclusion criteria

• Patients cannot be evaluated.For example, not administered Exemestane (Aromasin).

Trial design

451 participants in 1 patient group

Exemestane

Description:

Patients taking Exemestane Tablets.

Treatment:

Drug: Exemestane